Eli Lilly plans to pursue an expedited approval for use as an obesity treatment following the strong results and approval for use as a type 2 diabetes medication.
The use of Tirzepatide as an obesity medication will expand its reach as a weight-loss medication and it will be accessible to more patients.
At this stage it is understood that Eli Lilly are unable to comment on Tirzepatide’s future availability as an obesity medication, but the firm recognizes that the obesity crisis drives a need for potential new treatments for this chronic disease.
Eli Lilly will be required to obtain licenses for Tirzepatide in the relevant countries and with the appropriate agencies before the medication will be available to patients.